Akeso survival data for ivonescimab misses expectations, STAT says

2 months ago 26

TipRanks

Sat, Apr 26, 2025, 9:50 AM 1 min read

While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won support successful China this week, the information connected diligent endurance did not conscionable expert expectations, Jonathan Wosen of STAT reports. In its submission to regulators, Akeso included information connected diligent survival, disclosing that an interim investigation pursuing 157 diligent deaths recovered that participants connected ivonescimab had a astir 22% reduced hazard of death, with a hazard ratio of 0.784, a institution spokesperson confirmed to STAT. That uncovering is not statistically significant, but it does conscionable marketplace expert expectations, according to Wosen. In an email to STAT, an Akeso spokesperson noted that the interim investigation was not powered for statistical value and that the institution plans to behaviour ceremonial analyses of endurance erstwhile 232 and 280 deaths person occurred successful the trial. Shares of Summit Therapeutics fell 37% to $23.21 pursuing the study earlier halting for news. BioNTech (BNTX) dropped 17% to $100.06 successful sympathy with Summit.